Yesterday's Washington Post highlighted a wide scale eeg-based neurofeedback trial being conducted by the NIMH for ADHD. To date, neurofeedback for ADHD has been a cottage industry with continued attempts to bring it into the mainstream. However, lack of consensus around efficacy and its cost relative to popping pills have hindered patient adoption. Given the powerful nature of ADHD meds, it will be tough to compete on the same playing field, however, should the trials shed positive light on neurofeedback's ability to treat less aggressive forms of ADHD (which I believe is quite likely) neurofeedback should become a first in line treatment for many psychiatric illnesses over the next decade.